Philip O Scumpia
Overview
Explore the profile of Philip O Scumpia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
3116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kelly-Scumpia K, Archang M, Purbey P, Yokota T, Wu R, McCourt J, et al.
iScience
. 2024 Sep;
27(9):110676.
PMID: 39262784
Classic Ehlers-Danlos syndrome (cEDS) is a genetic disorder of the connective tissue that is characterized by mutations in genes coding type V collagen. Wound healing defects are characteristic of cEDS...
2.
Butenko S, Nagalla R, Guerrero-Juarez C, Palomba F, David L, Nguyen R, et al.
Nat Commun
. 2024 Aug;
15(1):6820.
PMID: 39122702
Biomaterial wound dressings, such as hydrogels, interact with host cells to regulate tissue repair. This study investigates how crosslinking of gelatin-based hydrogels influences immune and stromal cell behavior and wound...
3.
Hong A, Piva M, Liu S, Hugo W, Lomeli S, Zoete V, et al.
Cancer Discov
. 2024 Jul;
14(7):1357.
PMID: 38946326
No abstract available.
4.
Purbey P, Seo J, Paul M, Iwamoto K, Daly A, Feng A, et al.
Cell Rep
. 2024 Jun;
43(6):114289.
PMID: 38833371
Type I interferon (IFN-I) and IFN-γ foster antitumor immunity by facilitating T cell responses. Paradoxically, IFNs may promote T cell exhaustion by activating immune checkpoints. The downstream regulators of these...
5.
Mayer D, Nelson M, Andriyanova D, Filler R, Okten A, Antao O, et al.
J Control Release
. 2024 May;
370:570-582.
PMID: 38734312
Current antigen delivery platforms, such as alum and nanoparticles, are not readily tunable, thus may not generate optimal adaptive immune responses. We created an antigen delivery platform by loading lyophilized...
6.
Goodwin G, ONeil K, Dekok M, Bengio M, Scumpia P, Roka A, et al.
Clin Pract Cases Emerg Med
. 2024 Mar;
8(1):72-73.
PMID: 38546318
Case Presentation: A 30-year-old male with a past medical history of hypertension and renal failure on peritoneal dialysis presented to the emergency department with a chief complaint of a rash...
7.
Feng A, Thomas B, Purbey P, de Melo F, Liu X, Daly A, et al.
Immunity
. 2024 Mar;
57(3):462-477.e9.
PMID: 38430908
Inducible nucleosome remodeling at hundreds of latent enhancers and several promoters shapes the transcriptional response to Toll-like receptor 4 (TLR4) signaling in macrophages. We aimed to define the identities of...
8.
Mayer D, Neslon M, Andriyanova D, Antao O, Chen J, Scumpia P, et al.
bioRxiv
. 2024 Feb;
PMID: 38352398
Current antigen delivery platforms, such as alum and nanoparticles, are not readily tunable, thus may not generate optimal adaptive immune responses. We created an antigen delivery platform by loading lyophilized...
9.
Algazi A, Moon J, Lao C, Chmielowski B, Kendra K, Lewis K, et al.
Cancer
. 2024 Jan;
130(10):1784-1796.
PMID: 38261444
Background: Aberrant PI3K/AKT signaling in BRAF-mutant cancers contributes to resistance to BRAF inhibitors. The authors examined dual MAPK and PI3K pathway inhibition in patients who had BRAF-mutated solid tumors (ClinicalTrials.gov...
10.
Tang R, Shang L, Scumpia P, Di Carlo D
Adv Healthc Mater
. 2023 Nov;
13(25):e2302477.
PMID: 37985462
Hydrogels are widely used for tissue engineering applications to support cellular growth, yet the tightly woven structure often restricts cell infiltration and expansion. Consequently, granular hydrogels with microporous architectures have...